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ORIGINAL ARTICLEBacillus cereus bacteraemia: comparison between haematologic and
nonhaematologic patientsS. Tusgul1,2, G. Prod’hom3, L. Senn1,4, R. Meuli5, P.-Y. Bochud1 and S. G. Giulieri1
1) Service of Infectious Diseases, 2) Service of Internal Medicine, Department of Medicine, 3) Institute of Microbiology, Department of Laboratories, 4) Service of
Hospital Preventive Medicine and 5) Department of Radiology, Lausanne University Hospital, Lausanne, SwitzerlandAbstractBacillus cereus bacteraemia can be severe, especially among patients with haematologic malignancy.We retrospectively reviewed ﬁrst episodes of
trueB. cereus bacteraemia (more thanone positive bottle plus signs of infection) at our institution between 1997 and 2013with the aim to compare
haematologic versus nonhaematologic patients and analyse episodeswith complicatedoutcome.Among56 episodes of positive-blood cultures for
B. cereus,21were considered signiﬁcant.Median agewas 54 years (range 23–82 years). Ten patients (48%) had a haematologicmalignancy; all were
neutropenic at the time of B. cereus bacteraemia. Nonhaematologic patients were either intravenous drug users (n = 3, 14%), polytraumatized
(n = 3, 14%) or had multiple chronic comorbidities (n = 5, 24%). Most episodes were hospital acquired (15, 71%). Sources of bacteraemia
were intravascular catheter (n = 11, 52%), digestive tract (n = 6, 29%), drug injection (n = 3, 14%) and wound (n = 1, 5%). Adequate antibiotic
therapy was provided to 18 patients (86%) during a median of 17 days (range 2–253 days). The intravascular catheter was removed in eight
cases (42%). Three haematologic patients had a complicated course with neurologic complications (meningoencephalitis and cerebral
abscesses). Complications appeared to be associated with catheter infection (100% of complicated cases vs. 29% of noncomplicated cases). In
conclusion, B. cereus bacteraemia can have a complicated course in a subset of patients, mainly those with haematologic malignancy. Catheter
infection may be associated with a worse outcome with frequent neurologic complications.
© 2017 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.
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E-mail: stefano.giulieri@chuv.chIntroductionBacillus cereus is a spore-building, Gram-positive rod that can
survive in extreme environmental conditions and can persist in
the hospital [1,2]. While B. cereus is often considered a
contaminant, it can also cause signiﬁcant disease, which mani-
fests in three distinct syndromes: food intoxication, localized
infection and bacteraemia, with the latter sometimes being
associated with haematogenous complications (e.g. endophtal-
mitis, cerebral abscesses) [3]. Certain clinical manifestations like© 2017 The Authors. Published by El
This is an open access artinecrotizing infections (e.g. endophtalmitis, fasciitis) might be
caused by the release of to exotoxins such as proteases,
phospholipases and haemolysins [2,4,5].
It is widely recognized that haematologic patients have a
higher risk for invasive B. cereus infection [5–8], but few data
are available on other risk factors for complications of B. cereus
bacteraemia (such as mortality and metastatic infections). The
aims of the present study were to compare episodes between
haematologic and nonhaematologic patients and to identify
possible risk factors that may predispose patients to a compli-
cated course of B. cereus bacteraemia.
Patients and MethodsDeﬁnition of cases
Cases with more than one positive blood culture bottle for
B. cereus occurring at our institution (a 1500-bed universityNew Microbe and New Infect 2017; 15: 65–71
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through the microbiologic database. We included all patients
presenting with a ﬁrst episodes of true B. cereus bacteraemia,
deﬁned as more than one positive blood culture bottles and
signs of sepsis [9] or localized infection.
Data collection
The following data were extracted from patient charts: de-
mographic characteristics, site of hospitalization, underlying
disease, presence of neutropenia (neutrophil count <0.5 × 109/
L), previous chemotherapy, treatment with corticoids or other
immunosuppressive drugs, source of bacteraemia, presence of a
central venous catheter (CVC) and its management, symptoms
and signs of sepsis and localized infection and antibiotic treat-
ment. Outcome criteria were mortality at 30 days, presence of
haematogenous complications (meningitis, cerebral abscesses,
infective endocarditis or endophtalmitis) and relapse of B. cereus
bacteraemia.
The study was approved by the local institutional review
board of the University of Lausanne, Switzerland.
Identiﬁcation and antibiotic susceptibility
B. cereus was identiﬁed from blood cultures through Gram stain
appearance, colony morphology and haemolysis on blood agar,
positive lecithinase on egg yolk agar or matrix-assisted laser
desorption/ionization time-of-ﬂight mass spectrometry
(MALDI-TOF MS). Antimicrobial susceptibility testing was
performed using disk diffusion and was interpreted according to
Clinical and Laboratory Standards Institute criteria used for
staphylococci (due to the absence of criteria for Bacillus species
other than B. anthracis) until 2010, and Etest interpreted with
nonspeciﬁc European Committee for Antimicrobial Suscepti-
bility Testing (EUCAST) criteria for Gram-positive bacteria was
used thereafter.
Deﬁnitions of source of bacteraemia, adequate
antibiotic treatment and complicated bacteraemia
Bacteraemia was categorized as hospital onset if it occurred
>48 hours after admission. The source of B. cereus bacter-
aemia was ascertained by using the following criteria: for
catheter-related bloodstream infection (CRBSI), no apparent
source for bloodstream infection except catheter or positive
catheter tip culture for B. cereus (15 CFU); for digestive
tract, signiﬁcant abdominal disease conﬁrmed by imaging (e.g.
ileus, perforation) or neutropenic enterocolitis (clinical or
radiologic signs); for drug injection, active intravenous drug
use (IVDU) and temporal association between B. cereus
bacteraemia and drug injection; and for open fracture/
wound, sign of infection or wound culture positive for
B. cereus.© 2017 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microb
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/liceAntibiotic treatment was considered adequate if the B. cereus
isolate was susceptible to the antimicrobial prescribed (or if
there was a high likelihood of susceptibility based on published
data [10]) and dosed in accordance with current recommen-
dations. Antibiotic treatment was categorized as empirical if
administered within 24 hours of collection of the blood culture
and before susceptibility was known. Targeted antibiotic
treatment referred to the treatment continued or initiated on
the day that antibiogram results were reported. Haematoge-
nous complications were deﬁned by using following criteria: for
meningitis, at least one clinical sign (headache, neck stiffness,
impaired level of consciousness) associated with pleocytosis
(>4 white blood cells/mm3); for brain abscess, at least one
clinical sign (headache, focal neurologic deﬁcit, impaired level of
consciousness) and radiologic evidence; for infective endo-
carditis, deﬁnite diagnosis according to the Duke criteria [11];
and endophtalmitis, clinical signs and positive ophthalmologic
examination.
Statistical analysis
For comparison between groups, we used Fisher’s exact test
for categorical variables and the Mann-Whitney test for
continuous variables. Calculations were performed with Stata
12.0 (StataCorp, College Station, TX, USA) and GraphPad
Prism 6.00 (GraphPad Software, La Jolla, CA, USA).ResultsClinical characteristics
During the study period, we identiﬁed 56 episodes of positive
blood cultures for B. cereus, among which 33 were excluded
due to contamination (n = 31), relapse (n = 1) and missing
clinical data (n = 1); 21 were retained as true bacteraemia.
Among those, median patient age was 54 years (range 23–82
years) and the majority were men (n = 14, 67%). Underlying
haematologic malignancy was observed in 10 patients (48%),
chronic disease associated with some form of immunosup-
pression (autoimmune hepatitis, solid tumour, end-stage renal
disease, diabetes mellitus) in ﬁve (24%), IVDU in three (14%)
and polytrauma in three (14%). Six patients (29%) experienced
breakthrough bacteraemia while receiving antibiotic treatment
with cephalosporins or penicillins. The annual incidence of
B. cereus bacteraemia stratiﬁed according to underlying condi-
tion is shown in Fig. 1. Of note, three cases among haemato-
logic patients clustered in the ﬁrst months of 2013. However,
no common source of infection was identiﬁed.
Most episodes were hospital onset (71%). Community-onset
episodes were either associated with IVDU or end-stage renal
disease. Fever was present in 18 patients (86%), abdominaliology and Infectious Diseases, NMNI, 15, 65–71
nses/by-nc-nd/4.0/).
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FIG. 1. Timing of infection and un-
derlying diseases. Haematologic dis-
ease (n = 10): acute myeloid leukemia
(n = 5), myelodysplastic syndrome
(n = 3), acute lymphatic leukemia
(n = 2). Chronic disease (n = 4): end-
stage renal disease (n = 2), autoim-
mune hepatitis (n = 1), diabetes mel-
litus (n = 1), pseudomyxoma
peritonei (n = 1). Polytrauma (n = 3).
Intravenous drug use (IVDU, n = 3).
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FIG. 2. Antibiotic susceptibility of 21 Bacillus cereus strains. I, inter-
mediate; R, resistant; S, susceptible.
NMNI Tusgul et al. B. cereus bacteraemia in haematologic patients 67symptoms (i.e. abdominal pain, vomiting, diarrhea) in six (29%),
neurologic symptoms (including confusion, lethargy, generalized
headache, blurred vision, photopsia, dysarthria, dysdiadocho-
kinesia, hemiparesis and hemineglect) in four (19%).
Source of B. cereus bacteraemia
The source of bacteraemia was CRBSI in 11 cases (52%): short-
term CVC (n = 5), port (n = 3), tunnelled haemodialysis cath-
eter (n = 2) and arterial catheter (n = 1). In six cases (29%)
bacteraemia originated from the digestive tract: all patients with
an abdominal source had either abdominal symptoms (n = 4) or
pathologic ﬁndings on computed tomography (n = 4; bowel wall
thickening, ileus). Finally, source of infection was drug use in
three (14%) and wound infection (conﬁrmed by multiple posi-
tive wound swab cultures) in one (5%).
Microbiology
Concomitant pathogens were identiﬁed in seven episodes of
B. cereus bacteraemia. The frequency of polymicrobial infections
was similar between haematologic and nonhaematologic patients.
Cerebrospinal ﬂuid was collected in two cases (IVDU-associated
bacteraemia and meningoencephalitis) and was sterile. Results of
susceptibility testing are shown in Fig. 2. All tested isolates were
susceptible to vancomycin (20/20), ﬂuoroquinolones (16/16),
gentamicin (9/9) and cotrimoxazole (8/8), while they were
resistant to penicillin (18/18) and ceftriaxone (16/16). Imipenem
susceptibility was assessed in nine cases. One isolate had a min-
imal inhibitory concentration (MIC) of 3 mg/L. Only three of
seven tested isolates were susceptible to clindamycin.
Treatment characteristics
Empirical treatment (including vancomycin or carbapenems)
was adequate in six cases (26%), while adequate targeted© 2017 The Authors. Published by Elsevier Ltd on behal
This is an open access artictreatment was administered in 18 cases (86%). Two immuno-
competent patients (one IVDU and one polytraumatized) were
treated with amoxicillin/clavulanic acid, and a haematologic
patient was treated with imipenem despite an MIC of 3 mg/L.
Of note, no complication was observed among these patients
treated with inadequate antibiotics.
Median duration of adequate antibiotic treatment was 16.5
days (range 2–253 days). Nineteen patients (91%) had a CVC at
time of B. cereus bacteraemia. The CVC was removed in eight
cases (42%), including three cases of CRBSI. Median delay to
device removal was 1.5 days (range 0–16 days).
Haematologic patients
All but one patient with haematologic diseases had nosocomial
bacteremia and were neutropenic at time of bacteraemia. Me-
dian duration of neutropenia was 11 days (range 5–180 days).
Eight patients had either induction or consolidationf of European Society of Clinical Microbiology and Infectious Diseases, NMNI, 15, 65–71
le under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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tered to seven patients). Sources of bacteraemia were the in-
testinal tract (n = 5, 50%) and the CVC (n = 5, 50%).
In this group, median delay to adequate antibiotic treatment
was 1 day (range 0–7 days). The CVC was removed in 42% of
cases after a median delay of 4.5 days. No signiﬁcant difference
in clinical and treatment characteristics was found between
haematologic and nonhaematologic patients (Table 1).
Complications of B. cereus bacteraemia
Three patients (14%) had central nervous system (CNS) com-
plications: one had meningoencephalitis (impaired mental sta-
tus, cerebrospinal ﬂuid pleocytosis) and two had cerebral
abscesses. An illustrative case of CNS abscess is depicted in
Fig. 3. In the other case, B. cereus bacteraemia and cerebral
abscesses appeared 1 month after stopping antibiotic treatment
for the ﬁrst episode, which was managed with port retention
and vancomycin lock. All three patients with neurologic com-
plications had a haematologic malignancy. No other hematog-
enous complications, such as infective endocarditis
(echocardiography was performed in nine patients, two of
whom underwent transoesophageal echocardiography) or
endophtalmitis, were identiﬁed.
Two patients died during the 30 days after B. cereus bac-
teraemia (10%). One death in a patient with autoimmune
hepatitis was possibly related to B. cereus bacteraemia, while the
other patient died of invasive aspergillosis.TABLE 1. Patient characteristics
Characteristic
Haematologic
(n[ 10)
Nonhaematologic
(n[ 11)
Age (years) 55.5 (27–78) 44 (23–82)
Men 6 (60) 8 (73)
Nosocomial acquisition 9 (90) 6 (55)
Source of infection
CRBSI 5 (50) 6 (55)
Digestive tract 5 (50) 1 (9)
IVDU 0 3 (27)
Open fracture/wound 0 (0) 1 (9)
Polymicrobial infection 4 (40) 3 (27)
Neutropenia duration before
bacteraemia (days)
11 (5–180) NR
Mucositis 5 (50) NR
Fever 10 (100) 8 (73)
Adequate antibiotic treatment 9 (90) 9 (82)
Vancomycin 2 (22) 4 (44)
Imipenem 5 (56) 4 (44)
Other 2 (22) 1 (12)
Duration of adequate treatment (days) 18 (13–253) 14 (2–84)
Presence of catheter at time
of bacteraemia
10 (100) 9 (82)
Catheter removal 4 (40) 4 (44)
Delay until catheter removal (days) 4.5 (1–16) 1 (0–2)
Hospitalization in ICU 4 (40) 4 (36)
Relapse 1 (10) 0
Death at 30 days 1 (10) 1 (9)
Values are median (range) or n (%). No signiﬁcant difference was found between
haematologic and nonhaematologic patients.
CRBSI, catheter-related bloodstream infection; ICU, intensive care unit; IVDU,
intravenous drug use; NR, not reported.
FIG. 3. Brain imaging of haematogenous cerebral abscesses compli-
cating Bacillus cereus bacteraemia in a 63-year-old man with relapsing
acute myeloid leukemia. At day 13 after induction chemotherapy, the
patient presented with neutropenic fever, headache, photopsia and left
leg paresis. Magnetic resonance imaging (MRI) at ﬁrst neurologic
symptoms revealed a focal lesion in the paracentral lobule with focal
oedema and contrast enhancement on T2- and T1-weighted images
(arrows) (A). B. cereus was grown from blood cultures on the same day.
Contrast-enhanced computed tomography performed to investigate
neurologic deterioration (progression of paresis, lethargy and hemi-
neglect) showed a signiﬁcant increase in perilesional edema and
appearance of new abscesses (arrowhead) (B). Antibiotic therapy
(imipenem switched to oral levoﬂoxacin at discharge), initially associ-
ated with high-dose corticoids, was carried on for a total of 8.5 months.
Neurologic deﬁcits regressed completely. Last follow-up MRI T2- and
T1-weighted images showed an inactive lesion with minimal gliosis and
no contrast enhancement (arrowhead) (C).
© 2017 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases, NMNI, 15, 65–71
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haematologic diseases were heterogeneous, we limited the
analysis of complications to haematologic patients (Table 2).
While demographics and underlying disease did not differ be-
tween the two groups, CRBSI was the source of bacteraemia in
all complicated cases as compared to 29% of uncomplicated
cases. Overall, catheter management was similar between the
two groups. Of note, the only recurrence was related to
catheter retention.DiscussionIn this series of 21 patients with B. cereus bacteraemia, we
identiﬁed four distinct groups of patients according to their
underlying condition: haematologic malignancies, chronic dis-
eases (e.g. solid tumour, end-stage renal disease), typically
associated with a lower degree of immunosuppression as
compared to haematologic malignancies, polytrauma and IVDU.
Haematologic patients are a well-known risk group for
B. cereus bacteraemia due to neutropenia and a break in the
mucosal barrier after high-dose chemotherapy [12] and the skin
barrier due to CVCs. B. cereus colonizes not only the envi-
ronment and skin but also the intestinal tract, as shown in stool
studies of healthy subjects and hospitalized patients [13]. Au-
topsies of patients with fatal B. cereus bacteraemia have revealed
necrotizing intestinal lesions, highlighting the association be-
tween mucositis/neutropenic enterocolitis and B. cereus bac-
teraemia [14,15]. Our series highlights the important role ofTABLE 2. Risk factors for complicated outcome in
haematologic patients
Characteristic
Complicated
(n[ 3)
Not complicated
(n[ 7)
Age (years) 57 (46–64) 54 (27–78)
Male 2 (33) 4 (57)
Active haematologic disease
Myelodysplastic syndrome 1 (33) 2 (29)
AML 2 (66) 3 (43)
ALL 0 (0) 2 (29)
Cytarabine chemotherapy 2 (66) 5 (71)
Source of infection
Catheter-related bloodstream infection 3 (100) 2 (29)
Digestive tract 0 (0) 5 (71)
Intestinal mucositis 0 (0) 4 (57)
Skin rash 1 (33) 3 (43)
Polymicrobial infection 1 (33) 3 (43)
Adequate antibiotic treatment (days) 3 (100) 6 (86)
Duration 21 (15–253) 17.5 (13–20)
Delay until adequate antibiotic 1 (1) 4 (0–7)
Presence of catheter at time of bacteraemia 3 (100) 7 (100)
No catheter removal 1 (33) 5 (71)
Delay until removal (days) 3 (1–5) 10 (4–16)
Hospitalization in ICU 2 (66) 2 (29)
ICU days of hospitalization 8.5 (4–13) 10.5 (4–17)
Death at 30 days 0 (0) 1 (14)
Values are median (range) or n (%).
ALL, acute lymphoblastic leukaemia; AML, acute myeloid leukaemia; CRBSI,
catheter-related bloodstream infection; ICU, intensive care unit.
© 2017 The Authors. Published by Elsevier Ltd on behal
This is an open access articneutropenia (90% of patients), cytarabine chemotherapy (70%)
and enterocolitis (50%) in the pathogenesis of invasive B. cereus
disease. The median delay of 11 days between onset of neu-
tropenia and B. cereus bacteraemia suggests that B. cereus
infection is a late event in the course of neutropenia, unlike
other bacterial infections (e.g. Gram-negative or streptococcal
bacteraemia). This is most likely explained by resistance to the
β-lactams commonly used for the initial treatment of febrile
neutropenia. Intravascular catheters are an important risk fac-
tor for B. cereus bacteraemia in this population of patients.
B. cereus is able to produce bioﬁlms and adhere to foreign
bodies [2,17], thus preventing eradication of infection. Guide-
lines for the management of CRBSI recommend removing the
CVC within 72 hours of onset of B. cereus bacteraemia [18], as
studies indicate that the risk of recurrence is higher if the
catheter is retained [19–21]. Our own case of recurrence
conﬁrms this risk.
A striking feature of B. cereus among haematologic patients is
the ability to invade the CNS and produce meningitis, abscesses
or haemorrhage [14,22–25]. The pathogenesis of CNS invasion
is unknown. Intrathecal chemotherapy has been discussed by
some authors [7], but it is unlikely to explain most of the cases
because the association with bacteraemia points to a haema-
togenous route of infection. In our series, neurologic compli-
cations were found in three of ten haematologic patients. The
outcome was favourable with long-term antibiotic treatment,
and no drainage of the cerebral abscesses was necessary.
We tried to identify risk factors for CNS involvement in
haematologic patients by comparing episodes complicated by
CNS disease with uncomplicated episodes. The only possible
predictor was catheter-related infection: all three patients with
CNS complications had CRBSI, while among patients with un-
complicated course the digestive tract was the most common
source. Although the small sample size prevents us from drawing
a deﬁnitive conclusion, we believe that this is an interesting
observation. Two previous studies have addressed risk factors
for complications of B. cereus bacteraemia in haematologic pa-
tients. In a review of 46 published episodes, possible predictors
of poor outcome were neutropenia, presence of a CVC and
neurologic symptoms [5]. A paediatric study of 12 patients
identiﬁed corticosteroid and cephalosporin exposure, neu-
tropenia and intrathecal therapy as possible risk factors for CNS
complications [7]. Some authors have described an association
with intestinal mucositis [7,8]. None of our patients with CNS
complications experienced abdominal symptoms.
Previous studies have highlighted the presence of a CVC as a
risk factor for poor outcome [5,22] and recurrence [6,19,20].
To our knowledge, this is the ﬁrst description of a possible
association between catheter infection and complicated
B. cereus bacteraemia.f of European Society of Clinical Microbiology and Infectious Diseases, NMNI, 15, 65–71
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are usually localized infections. In contrast, B. cereus bacter-
aemia is rarely reported, with the notable exception of IVDU,
where infections are related to heroin contamination [26,27].
Bacteraemia is often transient; however, complications such as
endocarditis and endophtalmitis may occur [3]. In our series,
B. cereus bacteraemia among IVDU had a benign course, even
without adequate antibiotic treatment, thus calling into ques-
tion the role of antibiotic treatment of B. cereus bacteraemia
with spontaneous resolution.
B. cereus is usually resistant to all β-lactams except carba-
penems via a broad-spectrum β-lactamase [10]. As shown in
our series, resistance to carbapenems may occur, as already
described in studies from Japan [22,28–30]. Resistance to
clindamycin and ﬂuoroquinolones has also been reported
[22,31]. Antibiotic treatment should be tailored according to
susceptibility testing; no data are available to recommend spe-
ciﬁc regimens.
Our study has several limitations. First, because of the small
sample size, it was underpowered to compare clinical charac-
teristics of patients according to underlying conditions or to
identify further risk factors for complicated B. cereus bacter-
aemia. Second, when dealing with B. cereus, contamination is
always an issue. We made every effort to exclude blood culture
contamination by selecting only cases with at least two positive
blood culture bottles and associated compatible symptoms.
Third, in the absence of positive cultures of the affected site,
both the source attribution of B. cereus bacteraemia and the
deﬁnition of CNS involvement may be arbitrary. Deﬁnition of
CRBSI is particularly difﬁcult, because the CVC was removed in
less than half of cases. Therefore, like others [19], we relied on
the indirect criteria of absence of an alternative source. Finally,
management of patients has changed during the 16-year-long
study period. This may have affected our ability to compare the
episodes.
In conclusion, while B. cereus bacteraemia is mostly benign,
its clinical course can be severe in a subset of patients. Hae-
matologic disease and catheter-related infection appear to be
risk factors for a complicated course. Optimal management in
this patient group includes adequate antibiotic therapy and
catheter removal unless an alternative source is apparent (e.g.
intestinal mucositis). Future studies should further characterize
predictors of a complicated course among both haematologic
and nonhaematologic patients.
AcknowledgementWe thank H. Alwan for English-language revision.© 2017 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microb
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/liceConﬂict of InterestNone declared.References[1] Dubouix A, Bonnet E, Alvarez M, Bensaﬁ H, Archambaud M,
Chaminade B, et al. Bacillus cereus infections in traumatology–
orthopaedics department: retrospective investigation and improve-
ment of healthcare practices. J Infect 2005;50:22–30.
[2] Kotiranta A, Lounatmaa K, Haapasalo M. Epidemiology and patho-
genesis of Bacillus cereus infections. Microbes Infect 2000;2:189–98.
[3] Tuazon CU, Murray HW, Levy C, Solny MN, Curtin JA, Sheagren JN.
Serious infections from Bacillus sp. JAMA 1979;241:1137–40.
[4] Bottone EJ. Bacillus cereus, a volatile human pathogen. Clin Microbiol
Rev 2010;23:382–98.
[5] Inoue D, Nagai Y, Mori M, Nagano S, Takiuchi Y, Arima H, et al.
Fulminant sepsis caused by Bacillus cereus in patients with hematologic
malignancies: analysis of its prognosis and risk factors. Leuk Lymphoma
2010;51:860–9.
[6] Cotton DJ, Gill VJ, Marshall DJ, Gress J, Thaler M, Pizzo PA. Clinical
features and therapeutic interventions in 17 cases of Bacillus bacter-
emia in an immunosuppressed patient population. J Clin Microbiol
1987;25:672–4.
[7] Gaur AH, Patrick CC, McCullers JA, Flynn PM, Pearson TA,
Razzouk BI, et al. Bacillus cereus bacteremia and meningitis in immu-
nocompromised children. Clin Infect Dis 2001;32:1456–62.
[8] Rhee C, Klompas M, Tamburini FB, Fremin BJ, Chea N, Epstein L, et al.
Epidemiologic investigation of a cluster of neuroinvasive Bacillus cereus
infections in 5 patients with acute myelogenous leukemia. Open Forum
Infect Dis 2015;2:ofv096.
[9] American College of Chest Physicians; Society of Critical Care Medi-
cine. American College of Chest Physicians/Society of Critical Care
Medicine Consensus Conference: deﬁnitions for sepsis and organ
failure and guidelines for the use of innovative therapies in sepsis. Crit
Care Med 1992;20:864–74.
[10] Turnbull PC, Sirianni NM, LeBron CI, Samaan MN, Sutton FN,
Reyes AE, et al. MICs of selected antibiotics for Bacillus anthracis, Ba-
cillus cereus, Bacillus thuringiensis, and Bacillus mycoides from a range of
clinical and environmental sources as determined by the Etest. J Clin
Microbiol 2004;42:3626–34.
[11] Li JS, Sexton DJ, Mick N, Nettles R, Fowler Jr VG, Ryan T, et al.
Proposed modiﬁcations to the Duke criteria for the diagnosis of
infective endocarditis. Clin Infect Dis 2000;30:633–8.
[12] Hogan WJ, Letendre L, Litzow MR, Tefferi A, Hoagland HC, Pruthi RK,
et al. Neutropenic colitis after treatment of acute myelogenous leu-
kemia with idarubicin and cytosine arabinoside. Mayo Clin Proc
2002;77:760–2.
[13] Thuler LC, Velasco E, de Souza Martins CA, de Faria LM, da
Fonseca NP, Dias LM, et al. An outbreak of Bacillus species in a cancer
hospital. Infect Control Hosp Epidemiol 1998;19:856–8.
[14] Akiyama N, Mitani K, Tanaka Y, Hanazono Y, Motoi N, Zarkovic M,
et al. Fulminant septicemic syndrome of Bacillus cereus in a leukemic
patient. Intern Med 1997;36:221–6.
[15] Le Scanff J, Mohammedi I, Thiebaut A, Martin O, Argaud L, Robert D.
Necrotizing gastritis due to Bacillus cereus in an immunocompromised
patient. Infection 2006;34:98–9.
[17] Auger S, Ramarao N, Faille C, Fouet A, Aymerich S, Gohar M. Bioﬁlm
formation and cell surface properties among pathogenic andiology and Infectious Diseases, NMNI, 15, 65–71
nses/by-nc-nd/4.0/).
NMNI Tusgul et al. B. cereus bacteraemia in haematologic patients 71nonpathogenic strains of the Bacillus cereus group. Appl Environ
Microbiol 2009;75:6616–8.
[18] Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O’Grady NP, et al.
Clinical practice guidelines for the diagnosis and management of
intravascular catheter-related infection: 2009 update by the Infectious
Diseases Society of America. Clin Infect Dis 2009;49:1–45.
[19] Kassar R, Hachem R, Jiang Y, Chaftari AM, Raad I. Management of
Bacillus bacteremia: the need for catheter removal. Medicine (Balti-
more) 2009;88:279–83.
[20] Park HG, Choi SH. Long-term central venous catheter salvage in pa-
tients with Bacillus bacteremia. Medicine (Baltimore) 2010;89:346.
[21] Srivaths PR, Rozans MK, Kelly Jr E, Venkateswaran L. Bacillus cereus
central line infection in an immunocompetent child with hemophilia.
J Pediatr Hematol Oncol 2004;26:194–6.
[22] Uchino Y, Iriyama N, Matsumoto K, Hirabayashi Y, Miura K, Kurita D,
et al. A case series of Bacillus cereus septicemia in patients with he-
matological disease. Intern Med 2012;51:2733–8.
[23] Hansford JR, Phillips M, Cole C, Francis J, Blyth CC, Gottardo NG.
Bacillus cereus bacteremia and multiple brain abscesses during acute
lymphoblastic leukemia induction therapy. J Pediatr Hematol Oncol
2014;36:e197–201.
[24] Psiachou-Leonard E, Sidi V, Tsivitanidou M, Gompakis N,
Koliouskas D, Roilides E. Brain abscesses resulting from Bacillus
cereus and an Aspergillus-like mold. J Pediatr Hematol Oncol 2002;24:
569–71.© 2017 The Authors. Published by Elsevier Ltd on behal
This is an open access artic[25] Vodopivec I, Rinehart EM, Grifﬁn GK, Johncilla ME, Pecora N,
Yokoe DS, et al. A cluster of CNS infections due to B. cereus in the
setting of acute myeloid leukemia: neuropathology in 5 patients.
J Neuropathol Exp Neurol 2015;74:1000–11.
[26] McLauchlin J, Mithani V, Bolton FJ, Nichols GL, Bellis MA, Syed Q, et al.
An investigation into the microﬂora of heroin. J Med Microbiol
2002;51:1001–8.
[27] Tuazon CU, Hill R, Sheagren JN. Microbiologic study of street heroin
and injection paraphernalia. J Infect Dis 1974;129:327–9.
[28] Katsuya H, Takata T, Ishikawa T, Sasaki H, Ishitsuka K, Takamatsu Y,
et al. A patient with acute myeloid leukemia who developed fatal
pneumonia caused by carbapenem-resistant Bacillus cereus. J Infect
Chemother 2009;15:39–41.
[29] Kiyomizu K, Yagi T, Yoshida H, Minami R, Tanimura A, Karasuno T,
et al. Fulminant septicemia of Bacillus cereus resistant to carbapenem in
a patient with biphenotypic acute leukemia. J Infect Chemother
2008;14:361–7.
[30] Sakai C, Iuchi T, Ishii A, Kumagai K, Takagi T. Bacillus cereus brain
abscesses occurring in a severely neutropenic patient: successful
treatment with antimicrobial agents, granulocyte colony-stimulating
factor and surgical drainage. Intern Med 2001;40:654–7.
[31] Kobayashi K, Kami M, Ikeda M, Kishi Y, Murashige N, Tanosaki R, et al.
Fulminant septicemia caused by Bacillus cereus following reduced-
intensity umbilical cord blood transplantation. Haematologica
2005;90:ECR06.f of European Society of Clinical Microbiology and Infectious Diseases, NMNI, 15, 65–71
le under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
